{
    "Trade/Device Name(s)": [
        "Elecsys Tg II"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K221890",
    "Predicate Device Reference 510(k) Number(s)": [
        "K002905"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MSW"
    ],
    "Summary Letter Date": "April 21, 2023",
    "Summary Letter Received Date": "April 21, 2023",
    "Submission Date": "May 19, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Thyroglobulin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Li-Heparin)",
        "Plasma (K2-EDTA)",
        "Plasma (K3-EDTA)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "cobas e immunoassay analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Double antigen sandwich assay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys Tg II immunoassay for quantitative determination of thyroglobulin using ECLIA on cobas e analyzers",
    "Indications for Use Summary": "In vitro quantitative determination of thyroglobulin in human serum and plasma to aid in monitoring for persistent or recurrent/metastatic disease in differentiated thyroid cancer patients post-thyroidectomy, for use on cobas e immunoassay analyzers.",
    "fda_folder": "Immunology"
}